These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16771833)

  • 1. Evidence for L-dopa incorporation into cell proteins in patients treated with levodopa.
    Rodgers KJ; Hume PM; Morris JG; Dean RT
    J Neurochem; 2006 Aug; 98(4):1061-7. PubMed ID: 16771833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective and neurotoxic roles of levodopa (L-DOPA) in neurodegenerative disorders relating to Parkinson's disease.
    Kostrzewa RM; Kostrzewa JP; Brus R
    Amino Acids; 2002; 23(1-3):57-63. PubMed ID: 12373519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro.
    Chan SW; Dunlop RA; Rowe A; Double KL; Rodgers KJ
    Exp Neurol; 2012 Nov; 238(1):29-37. PubMed ID: 22001774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.
    Müller T; Kuhn W
    Mov Disord; 2009 Jul; 24(9):1339-43. PubMed ID: 19425084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolism of L-DOPA and L-threo-3,4-dihydroxyphenylserine and their effects on monoamines in the human brain: analysis of the intraventricular fluid from parkinsonian patients.
    Maruyama W; Naoi M; Narabayashi H
    J Neurol Sci; 1996 Jul; 139(1):141-8. PubMed ID: 8836986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of specific oxidized amino acids on protein turnover in J774 cells.
    Dunlop RA; Dean RT; Rodgers KJ
    Biochem J; 2008 Feb; 410(1):131-40. PubMed ID: 17953511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired cardiovascular autonomic control in newly and long-term-treated patients with Parkinson's disease: involvement of L-dopa therapy.
    Bouhaddi M; Vuillier F; Fortrat JO; Cappelle S; Henriet MT; Rumbach L; Regnard J
    Auton Neurosci; 2004 Nov; 116(1-2):30-8. PubMed ID: 15556835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
    Gründig E; Gerstenbrand F
    Wien Klin Wochenschr; 1980 Dec; 92(24):868-71. PubMed ID: 7222702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.
    Lin JJ; Yueh KC; Lin SZ; Harn HJ; Liu JT
    J Neurol Sci; 2007 Jan; 252(2):130-4. PubMed ID: 17196621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.
    Blandini F; Fancellu R; Martignoni E; Mangiagalli A; Pacchetti C; Samuele A; Nappi G
    Clin Chem; 2001 Jun; 47(6):1102-4. PubMed ID: 11375298
    [No Abstract]   [Full Text] [Related]  

  • 18. Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology.
    Antkiewicz-Michaluk L; Krygowska-Wajs A; Szczudlik A; Romańska I; Vetulani J
    Biol Psychiatry; 1997 Sep; 42(6):514-8. PubMed ID: 9285087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-dopa therapy for Parkinson's disease: past, present, and future.
    Nagatsua T; Sawadab M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
    Davidson DF; Grosset K; Grosset D
    Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.